Treatment of SLE with anti-CD19 CAR-T cellsdoi:10.1038/s41581-022-00651-3Ellen F. CarneyNature Reviews NephrologyNature Publishing Group UKNature Reviews Nephrology
With this in mind, in the last decade, many efforts have been made to use other treatments for cancer in combination with tuberculosis to increase the effectiveness of CAR-T cell therapy, especially in solid tumors. The combination therapy results have promising consequences for tumor regression an...
We further evaluated the proliferation and persistence of CAR-T in vivo. Two patients reached the peak expansion of CAR-T cells in the CSF on day 8 (Fig.1b, c), which coincided with the disappearance of CSF blasts in the responding patients. However, patient 1 exhibited peak expansion on...
687Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial Xu Yanmei,中国医学科学院血液病医院(中国医学科学院血液学研究所) 688The Therapeutic Efficacy of CD19 Chimeric Antigen Recep...
superfamily of cytokines, induces B cell proliferation and differentiation that positively correlate with systemic lupus erythematosus (SLE). This anti-BLYS antibody was named belimumab and marketed as Benlysta by GlaxoSmithKline, becoming the first drug approved (2011) for the treatment of SLE [142]....
The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies effective to deplete B cells in the patient.
Though the field of cell therapy is relatively new, as an industry we have packed incredible progress into the last two decades; from the first effective CAR T cells developed by researchers in 2002 to six FDA-approved cell therapies for blood cancers now on the market, with the...
The emerging therapeutic approach of CAR-T cell therapy has sparked great interests, extensive studies in preclinical and clinical trials have revealed encouraging therapeutic efficacy in treating a variety of cancers, particularly in treating B-cell hematologic malignancies with CD19 CAR-T cells [3]....
In recent years, a popular view of the pathogenesis of autoimmune disorders has been that B-cell derived events are ancillary to a basic breakdown in T-cell tolerance, and that although autoantibodies are present, the effector function of T cells is the fundamental pathological component. However...
(EBV)-sensitized T cells that express a second generation CD19 CAR construct for the treatment of CD19+ relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin’s lymphoma and B-cell mediated autoimmune diseases including systemic lupus erythematosus (SLE) with kidney involvement ...